SIC
MIST icon

SJS Investment Consulting’s Milestone Pharmaceuticals MIST Stock Holding History

SJS Investment Consulting’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,000
Closed -$17.9K – 2951
2026
Q1 		$17.9K Hold
15,000
– – ﹤0.01% 697
2025
Q4 		$30.3K Buy
+15,000
New +$32.3K ﹤0.01% 515

Other funds holding MIST

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
BRG
Bay Rivers Group Williamsburg, Virginia $293M AUM 48.17% 1-Year Est. Return
OE
October Effect Virginia Beach, Virginia $106M AUM 85.28% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
SC
Stephenson & Company San Clemente, California $213M AUM 15.03% 1-Year Est. Return
TFG
Taylor Financial Group Roanoke, Virginia $182M AUM 21.76% 1-Year Est. Return
VR
Vision Retirement Ridgewood, New Jersey $414M AUM
BWG
Beta Wealth Group San Diego, California $267M AUM 18.9% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

SJS Investment Consulting's MIST Position: Q2 2026 in Review

SJS Investment Consulting sold out of Milestone Pharmaceuticals (MIST) in Q2 2026, closing a stake of 15,000 shares — an estimated $17.9K sold.

SJS Investment Consulting first reported a position in MIST in Q4 2025 and held it in 2 quarters. The position peaked at $30.3K in Q4 2025. 13 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • SJS Investment Consulting reported no remaining Milestone Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 15,000 Milestone Pharmaceuticals shares in Q2 2026, an estimated $17.9K.
  • SJS Investment Consulting first reported a position in Milestone Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • SJS Investment Consulting's Milestone Pharmaceuticals position peaked at $30.3K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.